-
24/09/2020 ore 18:31Consiglio di Amministrazione di Friulchem: approva la relazione semestrale al 30 giugno 2020
-
24/07/2020 ore 09:44FRIULCHEM: NOTIFICATO A CONSOB L’AGGIORNAMENTO DEL KID
-
06/07/2020 ore 09:41Friulchem ottiene in Francia l’autorizzazione per un’estensione del brevetto legato alle compresse masticabili FC-CUBES
-
08/05/2020 ore 09:56Friulchem: riconosciuto credito di imposta su costi di IPO per € 339 mila
-
30/04/2020 ore 19:12Il Consiglio di Amministrazione di Friulchem: approva la delibera quadro inerente al contratto di fornitura di materie prime con Evultis e attribuisce deleghe al consigliere Carlo Marelli
-
23/04/2020 ore 17:32Friulchem: Ordinary Shareholders' Meeting approves the Financial Statements as at 31 December 2019
-
24/03/2020 ore 17:59Friulchem: draft financial statements as at 31 December 2019 approved
-
23/03/2020 ore 12:31Coronavirus covid-19 emergency: Friulchem is continuing with production activities
-
11/03/2020 ore 11:58Friulchem grows in the USA and continues its internationalisation process with the acquisition of 13% of Pharmabbie Inc, American company specialised in the development of veterinary drugs to be administered with Friulchem’s FC-CUBE® technology
-
25/02/2020 ore 17:43Friulchem approves the framework resolution regarding the raw materials supply contract with Evultis
-
20/01/2020 ore 17:052020 Company events calendar
-
13/12/2019 ore 16:53Friulchem approves the transaction with related party
-
28/11/2019 ore 17:55Friulchem approves the framework resolution concerning the contract for the supply of raw materials with Evultis
-
15/10/2019 ore 07:15Friulchem obtains authorization for the marketing in South Africa of an antibiotic for human use with a wide spectrum of action for serious infections
Friulchem S.p.A. (AIM: FCM), announces that it has obtained, after a "registration process" of over 5 years, the authorization for the marketing in South Africa of a broad-spectrum antibiotic for human use (injectable betalactam belonging to the class of carbapenems for the treatment of serious infections) and to have entered into an agreement with a leading multinational pharmaceutical company - world leader in the distribution of generic drugs - for exclusive distribution in South Africa.
-
27/09/2019 ore 18:47Friulchem continues its internationalization process with the establishment of Friulchem USA Inc.
Friulchem S.p.A. (AIM: FCM) communicates the constitution of the Friulchem USA Inc. company. The newly company will be active in the marketing and distribution of feed supplement or non-pharmaceutical products for the North American veterinary sector.
-
27/09/2019 ore 09:30CEO at the 2019 semi-annual report
Disma Giovanni Mazzola, CEO of Friulchem S.p.A. (AIM: FCM) commented on the 2019 half-year figures
-
26/09/2019 ore 17:55Friulchem: the half-year report as of June 30, 2019 approved
-
29/07/2019 ore 17:58SIGNIFICANT SHAREHOLDERS (Available only in Italian)
-
25/07/2019 ore 18:01CORPORATE EVENTS CALENDAR 2019 (Available only in Italian)
-
23/07/2019 ore 18:37NOTIFIED TO CONSOB THE KID - "KEY INFORMATION DOCUMENT" CONCERNING THE "WARRANT FRIULCHEM 2019-2022"
-
23/07/2019 ore 16:25FRIULCHEM S.p.A. ADMITTED TO TRADING ON THE AIM ITALIA MARKET